Literature DB >> 7928185

The role of tumor necrosis factor-alpha in the induction of experimental autoimmune uveoretinitis in mice.

S Nakamura1, T Yamakawa, M Sugita, M Kijima, M Ishioka, S Tanaka, S Ohno.   

Abstract

PURPOSE: To examine the role of tumor necrosis factor-alpha (TNF) in the induction of experimental autoimmune uveoretinitis (EAU), the authors compared in vivo TNF production in EAU-susceptible and EAU-resistant strains of congenic mice and attempted to determine whether TNF can enhance the inflammation in EAU by injection of TNF at the time of immunization.
METHODS: The production of TNF after stimulation with lipopolysaccharide (LPS) in B10.A and B10.D2 mice was measured by bioassay with L929 cells. The incidence and severity of EAU was compared between the group immunized with conventional methods and the group that alternatively received additional subcutaneous injection of recombinant human TNF (rhTNF) at the time of immunization in both B10.A and B10.D2 mice.
RESULTS: Serum concentration of TNF after stimulation with 50 micrograms of LPS was significantly higher in B10.A mice than in B10.D2 mice. The incidence of EAU in B10.A mice was 60%, but it was only 10% in B10.D2 mice using the conventional method. Extremely severe chorioretinitis and iridocyclitis occurred in B10.A mice with the injection of rhTNF at the time of immunization for EAU. The incidence of EAU in B10.A and B10.D2 rose to 100% and 40%, respectively. When administered alone, rhTNF did not cause any inflammatory change in the uvea.
CONCLUSIONS: The rhTNF was found to enhance the immune response to interphotoreceptor retinoid-binding protein in mice. These results suggest that susceptibility to EAU is in some part mediated by the ability of mice to produce TNF.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7928185

Source DB:  PubMed          Journal:  Invest Ophthalmol Vis Sci        ISSN: 0146-0404            Impact factor:   4.799


  19 in total

Review 1.  Adalimumab (Humira™): a promising monoclonal anti-tumor necrosis factor alpha in ophthalmology.

Authors:  Piergiorgio Neri; Manuela Zucchi; Pia Allegri; Marta Lettieri; Cesare Mariotti; Alfonso Giovannini
Journal:  Int Ophthalmol       Date:  2011-02-02       Impact factor: 2.031

2.  Early cytokine and chemokine gene expression during Pseudomonas aeruginosa corneal infection in mice.

Authors:  K A Kernacki; D J Goebel; M S Poosch; L D Hazlett
Journal:  Infect Immun       Date:  1998-01       Impact factor: 3.441

Review 3.  Mitochondrial oxidative stress initiates visual loss in sympathetic ophthalmia.

Authors:  Yutaka Kaneko; Narsing A Rao
Journal:  Jpn J Ophthalmol       Date:  2012-04-03       Impact factor: 2.447

Review 4.  Cytokines and chemokines in uveitis: is there a correlation with clinical phenotype?

Authors:  Kenneth G-J Ooi; Grazyna Galatowicz; Virginia L Calder; Susan L Lightman
Journal:  Clin Med Res       Date:  2006-12

5.  An Update on Treatment of Pediatric Chronic Non-Infectious Uveitis.

Authors:  Arjun B Sood; Sheila T Angeles-Han
Journal:  Curr Treatm Opt Rheumatol       Date:  2017-01-29

6.  Infliximab exerts a dose-dependent effect on retinal safety in the albino rabbit.

Authors:  Shiri Zayit-Soudry; Igor Vainer; Esther Zemel; Michael Mimouni; Melvin Rabena; Dante J Pieramici; Ido Perlman; Anat Loewenstein
Journal:  Doc Ophthalmol       Date:  2017-08-19       Impact factor: 2.379

7.  Anti-TNF-alpha therapy for sight threatening uveitis.

Authors:  E W Lindstedt; G S Baarsma; R W A M Kuijpers; P M van Hagen
Journal:  Br J Ophthalmol       Date:  2005-05       Impact factor: 4.638

8.  Evaluation of potential retinal toxicity of adalimumab (Humira).

Authors:  Miltiadis Tsilimbaris; Vasilios F Diakonis; Irini Naoumidi; Spyridon Charisis; Iraklis Kritikos; George Chatzithanasis; Thekla Papadaki; Sotiris Plainis
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2009-03-19       Impact factor: 3.117

Review 9.  Biologic agents in experimental autoimmune uveitis.

Authors:  Gian Paolo Giuliari; Ama Sadaka; David M Hinkle
Journal:  Int Ophthalmol       Date:  2013-03-14       Impact factor: 2.031

10.  Adalimumab (humira™) in ophthalmology: a review of the literature.

Authors:  Piergiorgio Neri; Marta Lettieri; Cinzia Fortuna; Manuela Zucchi; Mara Manoni; Silvia Celani; Alfonso Giovannini
Journal:  Middle East Afr J Ophthalmol       Date:  2010-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.